

# Material Obsolescence Story MGMC 2025

Victoria Geisler  
Stephen Roller  
26 Aug 2025

**Johnson & Johnson**  
MedTech

# Obsolescence Key Players



**Ana Teresa Vargas**  
Project Manager



**Jon Burkhardt**  
MSM



**Marilyn Ocasio**  
MSM



**David Wetherell**  
Category



**Victoria Geisler**  
Supply Chain Lead



**Stephen Roller**  
Technical Lead

## Key numbers

---

# 1,414

Raw count of EM&E codes impacted by obsolescence & change events by 2024

---

# 12

Obsolescence events in 2025 alone

---


# \$MM

LTB inventory costs across portfolios

---


# Major Headwinds to our Reaction Time

## Product Focused Organizational Design for Technical Teams



Inconsistent validation strategies, differing priority levels, countless cooks in the kitchen

## Disparate Data Structures for Resin Utilization





Usage data difficult to calculate across distributors, component suppliers, internal and external manufacturers  
Led to oversized LTB, inventory fees, or unexpected runouts

## Evolving Regulatory Landscape, Sensitivity to Patient Contact



Complex implementations, long lead times for global registrations, complexity in delivery capabilities

# Material Obsolescence Core Team



**Dedicated engineers & support team to focus on material events that cross the business**

- Scoped to known obsolescence events but partnering with our initiatives
- When in doubt, reach out to the folks on the intro slide & we can get you to the right place

**Risk based testing strategy starting at the material level**

- The more detail you can provide about performance expectations of the change; the more streamlined we can make the implementation
- Building organizational trust that resin performance can and will translate to component performance (ISO-10993, NVR, FTIR, back-to-back TDS comparison, etc)

# Current Strategies

## PHASE 1: PROJECT INTAKE / IMPACT ASSESSMENT

## PHASE 2: FEASIBILITY / PLANNING

## PHASE 3: EXECUTION

Owner: MSM

Resin Material Vendor

Resin Category

Product Material Tech Team

Impact Assessment

FG Vendors

### Negotiation and Prioritization

SRMs

Value Stream Leads

Strategic Component Planning

### Technical Strategy / Feasibility Testing

Product SMEs

Material Partners

Plastics Development Engineers

Priorities / Critical Dates



### Executable Strategy

Oversight Manager / Team\*

PFT Team (Execution)

# Improved Systems Connectivity

- Dataset enabled by R-spec functionality in Granta
- Allows us to more quickly see across systems for impact
- Reduces lead times for impact assessments & improves confidence in leaner LTB quantities
- Currently enabled for EM&E core platforms with hopes to support improvements across MedTech



# Focused Regulatory & Toxicology Strategy

- Focused efforts with our regulatory & biocompatibility /toxicology partners have upskilled our teams and made our projects more predictable
- Able to register as alternatives to simplify supply chain control strategies

Small changes to material performance, nomenclature, or formulation change can have significant impact & heightened sensitivity world wide with regulatory bodies. This leads to supply risk & significant cost to change

## How you can help us

- More toxicology data that can be provided, the lower the risk & workload
  - ISO-10993 sections 4, 5, 6, 10, 11, and USP661 are preferred
- Back-to-back mechanical assessment for formulation changes (COA or TDS)
- Minimize changes of CAS#, nomenclature, or performance specs

# Discussion Opportunities for Continued Partnership



## Enabling PFAS removal agility

The groundwork we're laying is helping validation teams as they proactively look to move to a reduced PFAS portfolio

For proactive alternatives, reach out to Lourdes Palacio!



## Come with the data!

The more evidence you have at the initial event, the leaner our response can be



## Help us benchmark!

Are there strategies you've supported with other obsolescence events that could help improve our agility?



## Innovation

How can we lower the barrier to entry for new materials and technologies!

# Thank you

If you have more questions, please contact:

Victoria Geisler  
[vgeisler@its.jnj.com](mailto:vgeisler@its.jnj.com)

Or

Stephen Roller  
[sroller@its.jnj.com](mailto:sroller@its.jnj.com)

**Johnson & Johnson**  
MedTech